Bernd Kasper, MD, PhD, on Desmoid Tumors: Results on Nirogacestat vs Placebo

ESMO Congress 2022


Bernd Kasper, MD, PhD, of Germany’s Mannheim Cancer Center, discusses phase III data from the DeFi trial, the largest study conducted to date for patients with desmoid tumors. The trial showed that the gamma secretase inhibitor nirogacestat demonstrated improvements in all primary and secondary efficacy endpoints. Although considered benign because of their inability to metastasize, desmoid tumors can cause significant morbidity and, occasionally, mortality in patients (Abstract LBA2).


Disclaimer: This video transcript has not been proofread or edited and may contain errors.
It's my pleasure to speak about DeFi phase III trial of nirogacestat in progressing desmoid tumor patients and I had the pleasure to present that trial yesterday at ESMO 2022 in the presidential session. When talking about desmoid tumors, we are actually talking about a rare disease. They are locally aggressive and invasive soft tissue tumors that are somehow difficult to manage due to their variable presentations, the unpredictable clinical cause, and the lack of currently approved therapies. There is indeed a clear rationale for the use of gamma secretase inhibitors in this disease as desmoid tumors express [inaudible 00:00:47], which can be blocked by gamma secretase inhibitors. So nirogacestat is an investigational oral and selective small molecule gamma secretase inhibitor that already showed activity in phase I and II trials in desmoid tumors with a manageable safety profile. The phase III trial is a large global randomized double blind placebo-controlled trial, looking at safety, efficacy and tolerability of nirogacestat in comparison to placebo in resist progressing desmoid tumors. We actually randomized 142 patients in 37 sites all over the world and primary endpoint was progression-free survival and secondary endpoints included overall response rate, and a couple of different patient-reported outcome measures. So the results are as follows. The primary endpoint was met with improved progression-free survival, demonstrating a statistically significant 71% reduction in the risk of disease progression. And the confirmed objective response rate was 41% with nirogacestat as compared to 8% in the placebo arm. Again, highly statistically significant, including 7% complete responses with nirogacestat. The median time to response was 5.6 months with nirogacestat compared to 11 month in the placebo arm. In terms of safety, actually nirogacestat was well tolerated. 95% of all treatment emergent adverse events were grade I or II. The most frequent side effect with nirogacestat were diarrhea, rash, hyperphosphatemia and fatigue. And those reductions were necessary in about 40% of patients and were primarily due to diarrhea, rash, and stomatitis. In summary, DeFi represents the largest and most rigorous randomized controlled trial to-date in desmoid tumor. It actually definitely showed rapid, sustained and statistically significant improvements in all primary and secondary endpoints. It had a manageable safety profile with 95% of all the treatment emergent adverse events being grade I or II, and nirogacestat does have the potential to become the standard of care in desmoid tumors requiring systemic treatment. There are definitely a couple of open questions still from that trial. One question might be the lengths of treatment duration so there could be something like a discontinuation trial. But what we'd learned from that trial already that nirogacestat is absolutely feasible for long-term treatment in this patient population and we will investigate, of course, a lot of other questions as well.

Related Videos

Kidney Cancer

Toni K. Choueiri, MD, and Laurence Albiges, MD, PhD, on RCC: Review of Two Key Abstracts on Belzutifan Plus Cabozantinib and Pembrolizumab Plus Lenvatinib

Toni K. Choueiri, MD, of the Dana-Farber Cancer Institute, and Laurence Albiges, MD, PhD, of France’s Gustave Roussy Cancer Centre, discuss results from two important trials presented at ESMO 2022: Cohort 1 of the LITESPARK-003 study of belzutifan plus cabozantinib as first-line treatment of advanced renal cell carcinoma (RCC), and the KEYNOTE-B61 study of pembrolizumab plus lenvatinib as first-line treatment for non–clear cell RCC (Abstracts 1447O and 1448O).

Gynecologic Cancers

Paul A. DiSilvestro, MD, on Ovarian Cancer: New Data on Olaparib in Newly Diagnosed Disease

Paul A. DiSilvestro, MD, of Women & Infants Hospital and the Warren Alpert Medical School of Brown University, discusses overall survival results after a 7-year follow-up of the SOLO1/GOG-3004 trial for patients with newly diagnosed advanced ovarian cancer and a BRCA mutation who received maintenance olaparib. Dr. DiSilvestro details the increasing role of such PARP inhibitors in ovarian cancer treatment and their benefit to patients (Abstract 517O).

Skin Cancer

Neil D. Gross, MD, on Cutaneous Squamous Cell Carcinoma: Recent Findings on Cemiplimab

Neil D. Gross, MD, of The University of Texas MD Anderson Cancer Center, discusses data from a phase II study, which showed that neoadjuvant cemiplimab-rwlc in patients with stage II–IV (M0) resectable cutaneous squamous cell carcinoma is active and may enable function-preserving surgery in some cases (Abstract 789O).

Kidney Cancer

Nizar M. Tannir, MD, on RCC: Data on Bempegaldesleukin Plus Nivolumab vs Tyrosine Kinase Inhibitors in Untreated Disease

Nizar M. Tannir, MD, of The University of Texas MD Anderson Cancer Center, discusses phase III findings from the PIVOT-09 study, which compared bempegaldesleukin plus nivolumab with the investigator’s choice of a tyrosine kinase inhibitor (either sunitinib or cabozantinib) in patients with previously untreated advanced renal cell carcinoma (Abstract LBA68).

Colorectal Cancer

Marinde J.G. Bond, PhD Candidate, on Colorectal Liver Metastases: FOLFOX/FOLFIRI, Bevacizumab, and Panitumumab

Marinde J.G. Bond, PhD Candidate, of the University Medical Center, Utrecht, discusses phase III findings from the CAIRO5 study of the Dutch Colorectal Cancer Group, the first such trial in defined subgroups of patients with initially unresectable colorectal cancer liver metastases and left-sided and RAS/BRAF V600E wild-type tumor. The study compared FOLFOX/FOLFIRI plus either bevacizumab or panitumumab (Abstract LBA21).